FDA Drug recall D-0462-2022
Semglee (insulin glargine) injection, 100 units/mL (U-100), 3 mL Prefilled Pen (NDC 49502-0196-71), packaged in Five 3 mL Prefilled Pens pe…
- FDA Drug
- Class I
- terminated
- Published 2022-01-26
On 2022-01-26 the FDA classified a Class I recall of Semglee (insulin glargine) injection, 100 units/mL (U-100), 3 mL Prefilled Pen (NDC 49502-0196-71), packaged in Five 3 mL Prefilled Pens pe… by Mylan Pharmaceuticals, citing labeling: Missing Label: label missing from some Semglee prefilled pens.
Read the official FDA Drug notice
| Agency | FDA Drug |
|---|---|
| Recall number | D-0462-2022 |
| Classification | Class I |
| Status | terminated |
| Initiated | 2022-01-05 |
| Published | 2022-01-26 |
| Last updated | 2026-09-13 11:52 UTC |
| Company | Mylan Pharmaceuticals |
| Distribution | US |
Product
Semglee (insulin glargine) injection, 100 units/mL (U-100), 3 mL Prefilled Pen (NDC 49502-0196-71), packaged in Five 3 mL Prefilled Pens per carton (NDC 49502-0196-75), Rx only, Manufactured in Malaysia for: Mylan Specialty L.P., Morgantown, WV, 26505.
Reason
Labeling: Missing Label: label missing from some Semglee prefilled pens.
Identifiers
| code_info | Batch # BF20003118, Exp. August 2022 |
|---|
Status history
No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: terminated.
Source
Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0462-2022%22
RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.